ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1143

Increased Frequency Of Pratroling Monocytes In Experimental Arthritis and Rheumatoid Arthritis Patients In Response To IL6-R Blockade

Julie Quentin1, Jessy Presumey2, Florence Apparailly2, Yves-Marie Pers3, Pascale Louis Plence4 and Christian Jorgensen3, 1Inserm U844, Montpellier, France, 2U844, Inserm, Montpellier, France, 3Department of therapy & Immuno-Rhumatology, Inserm U844, CHU saint-Eloi, Université Montpellier 1, CHU Lapeyronie, Montpellier, France, 4INSERM U844 Montpellier, Montpellier, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: antigen-presenting cells, Autoinflammatory Disease, dendritic cells and natural killer (NK) cells, Fc receptors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innate Immunity and Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Monocytes represent a heterogeneous circulating population of immune cells that play important roles in the inflammatory response. Two main functional subsets of human monocytes have been identified, as well as their counterparts in mouse. Increasing numbers of reports suggest that each of them exert specific roles in homeostasis and inflammation in vivo, and their involvement in pathological inflammatory responses is growing. The aim of our study was to investigate the effect of the anti-IL6R antibody therapy, in the mouse CIA model and in Rheumatoid arthritis patients, on the frequencies of monocyte sub-populations. 

Methods:

The CIA has been induced by immunization of DBA1 mice with bovine type II collagen. The anti-IL6R antibody (MR16-1) treatment was initiated on day 22 post-immunization using i.p. injections of 0.5mg/mouse twice a week. Blood samples were collected weekly from day 23 and the different monocyte subsets were analyzed by flow cytometry.

15 RA patients were recruited and Tocilizumab was given with approval of the French Drug Agency, in a dose of 8 mg/Kg as a 60-minute intravenous infusion every 4 weeks. For immune monitoring, blood samples from RA patients were collected just before the 1st and 4th tocilizumab infusions (8 mg/Kg).

Results:

Clinical monitoring of CIA showed a stabilization of disease features from day 29 until euthanasia (D44) demonstrating that the anti-IL-6R Ab treatment was able to slowdown CIA progression and decrease disease severity when injected after the boost. We monitored the percentage of monocyte subsets and evidenced fluctuations during clinical course of the disease. The percentage of circulating inflammatory Ly6Chigh monocytes was transiently reduced on day 37 in the treated group as compared with controls, while the percentage of the non-inflammatory Ly6Clow monocytes was significantly increased from day 30.

In parallel, we have monitored monocytes cell populations in the blood of RA patients before and during treatment with Tociluzumab and found (1) fluctuations of monocyte subsets following Tociluzumab therapy and (2) significant difference in frequencies in the various subsets before treatment between responders and non-responders and (3) a correlation between clinical benefit and increased frequency of the non-classical CD14dimCD16+ monocytes.

Conclusion: Similar to the increased frequency of the non-classical CD14dimCD16+ monocytes that we observed in the blood from RA patients under Tocilizumab therapy, an increased percentage of their mouse counterpart Ly6Clow monocytes was observed following treatment of CIA mice with MR16-1 Ab. These data suggest new cellular mechanisms insight into clinical benefit associated with anti-IL6R-based therapy and suggest that frequency of the CD14dimCD16+ monocytes can predict clinical response to treatment.


Disclosure:

J. Quentin,
None;

J. Presumey,
None;

F. Apparailly,
None;

Y. M. Pers,
None;

P. Louis Plence,
None;

C. Jorgensen,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-frequency-of-pratroling-monocytes-in-experimental-arthritis-and-rheumatoid-arthritis-patients-in-response-to-il6-r-blockade/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology